




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07C 67/297, 69/54, C08F 120/20, G02B 1/04		A1	(11) International Publication Number: WO 00/63150
			(43) International Publication Date: 26 October 2000 (26.10.00)
(21) International Application Number: PCT/GB00/00780 (22) International Filing Date: 3 March 2000 (03.03.00) (30) Priority Data: 9908808.0 16 April 1999 (16.04.99) GB (71) Applicant (for all designated States except US): HYDRON LIMITED [GB/GB]; Hawley Lane, Farnborough, Hampshire GU14 8EQ (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): HOLDSTOCK, Barry, Charles [GB/GB]; Flat 12, Kingston Court, 82 Maple Road, Surbiton, Surrey KT6 4AL (GB). GLASBEY, Trevor, Owen [GB/GB]; 27 Kingston Road, Camberley, Surrey GU15 4AG (GB). (74) Agents: ALCOCK, David et al.; D. Young & Co., 21 New Fetter Lane, London EC4A 1DA (GB).			(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published With international search report.

(54) Title: PROCESS FOR THE PREPARATION OF A DIOL



(57) Abstract

There is provided a process for the preparation of a polymerisable composition comprising a cross-linker and a polymerisable monomer of formula (I) comprising the steps of: (i) contacting a compound of formula (II) with an immobilised acid, wherein X, Y, Z, R¹, P and Q are independently selected from a hydrocarbonyl group or hydrogen and wherein A is (CH₂)_n wherein n is 0 or 1; (ii) neutralising the product of step (i) such that the cross-linker is formed.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

PROCESS FOR THE PREPARATION OF A DIOL

The present invention relates to a process for the preparation of a diol. The diol may be used subsequently used as a monomer for the preparation of a polymeric device or material such as a hemocompatible coating, medical device, water soluble polymer
5 material, paint, water borne coating or an ocular device (such as a contact lens).

Polymers made from polymerisable monomers have wide spread applications. For example, polymers are used as additives for coating applications, such as paints and
10 adhesives. Polymers are also used to prepare lenses, such as contact lenses.

Polymers are prepared by polymerising one or more types of polymerisable monomers, such as by emulsion polymerisation, solution polymerisation, suspension polymerisation or bulk polymerisation. The monomer(s) may be polymerised in the presence of optional
15 ingredients such as any one of emulsifiers, stabilisers, surface active agents, initiators (such as photoinitiators), inhibitors, dispersants, oxidising agents, reducing agents, viscosity modifiers, catalysts, binders, activators, accelerators, tackifiers, plasticizers, saponification agents, chain transfer agents, surfactants, fillers, dyes, metal salts, and solvents.

20

There are numerous references on polymerisation of polymerisable monomers. For example, some teachings may be found in "Emulsion Polymerization: Theory and Practice" by D. C. Blackley (published by Wiley in 1975) and "Emulsion Polymerization" by F. A. Bovey *et al.* (published by Interscience Publishers in 1965). For example, a
25 polymer can be prepared from monomers such as methyl acrylate, ethyl acrylate, butyl acrylate, 2-ethylhexyl acrylate, decyl acrylate, methyl methacrylate, ethyl methacrylate, butyl methacrylate, styrene, butadiene, ethylene, vinyl acetate, vinyl esters, C₉, C₁₀ and C₁₁ tertiary monocarboxylic acids, vinyl chloride, vinyl pyridine, vinyl pyrrolidine, vinylidene chloride, acrylonitrile, chloroprene, acrylic acid, methacrylic acid, itaconic acid, maleic
30 acid and fumaric acid.

Examples of further teachings on polymerisation of polymerisable monomers may be found in "Vinyl and Related Polymers" by C.E. Schildknecht (New York: John Wiley & Sons 1952) and "Monomeric Acrylic Esters" by E.H. Riddle (New York: Reinhold Publishing Corp. 1954), and by A.G. Alexander (J Oil Colour Chemists' Association
5 [1962] 45 12) and G.G. Greth and J.E. Wilson (J Appl Polymer Sci [1961] 5 135).

More recent teachings regarding polymerisation methods may be found in EP-A-0622378, EP-A-0634428, EP-A-0623632, EP-A-0635522, EP-A-0633273, EP-A-0632157, EP-A-0630908, EP-A-0630641, EP-A-0628614, EP-A-0628610, EP-A-0622449, EP-A-
10 0626430 and EP-A-0625529.

As mentioned above, one particular application of polymers is in the preparation of lenses, especially contact lenses or intraocular lenses. Examples of teachings for the preparation of contact lenses may be found in EP-A-0359539, which discloses a method of forming a
15 soft contact lens. Other documents that describe the preparation of contact lenses include WO-A-9502617 which discloses a contact lens made from a vinyl polymer bearing phosphonium groups, JP-A-06313009 which discloses a contact lens made from a polymer having a terminal phosphoryl-choline group, WO-A-9429756 which discloses a gas permeable ocular lens made from a block copolymer and a second polymer
20 component. WO-A-9409042 which discloses a contact lens comprising polymer and a UV absorbing constituent, and WO-A-9211407 which discloses a tinted contact lens comprising a polymer and a dye wherein the lens is prepared by incorporating a dye into a hydrophilic polymer while the polymer is being formed. Further documents describing preparing contact lenses and the like from polymerisable monomers include EP-A-
25 0574352, EP-A-0439394, EP-A-0378511 and EP-A-0424520.

Whilst polymers can be fairly easily prepared from polymerisable monomers there can be a problem in reliably and cheaply obtaining suitable monomers in a satisfactory pure form. In this regard, many desired polymerisable monomers are supplied with impurities. These
30 impurities can be detrimental to the final product.

Impurities which are particularly problematic are compounds which act as cross-linkers during the polymerisation of the monomer. Whilst the presence of cross-linkers is often required during the polymerisation of a monomer, the presence of impurities which act as cross-linkers may cause at least two problems. Firstly, to achieve a desired degree of cross-linking during polymerisation, the addition of further cross-linker is often required. However, if the amount of cross-linker impurity present in the monomer is not known, the required amount of additional cross-linker cannot be readily calculated. Thus, controlling the degree of cross-linking may be difficult. Moreover, if cross-linker is present in an amount greater than is necessary to provide the required degree of cross-linking, cross-linker must be removed prior to polymerisation.

An example of a monomer in which impurities, in particular cross-linkers, are a problem is glyceryl methacrylate (GMA) which is a preferred monomer for preparing contact lenses. Examples of documents mentioning the use of such a monomer include US-A-5236969, JP-A-04335007, GB-A-2180243 and EP-A-0100381. There are two major problems with GMA. First, the impurities often vary from batch to batch and so make it difficult to have a standard purification protocol. Second, GMA is a very expensive monomer.

There have been attempts to prepare GMA from other monomers, such as isopropylidenglyceryl methacrylate (IPGMA) [i.e. 2,2-dimethyl-1,3-dioxolan-4-yl methyl methacrylate (GMAK)]. One such process for preparing GMA is disclosed in US-A-4056496 wherein the process includes reacting IPGMA with sulphuric acid and hydroquinone for a period of 16 hours.

Another process for preparing GMA, also mentioned in US-A-4056496, includes the hydrolysis of glycidyl methacrylate (GYMA) by treating GYMA with concentrated sulphuric acid for 6 days (M.F. Refojo [1965] Journal of Polymer Science 9 pp 3161-3170). This process is particularly disadvantageous because glycidyl methacrylate is highly toxic and carcinogenic. Moreover, glycidyl methacrylate is a cross-linker and further cross-linkers are formed during the reaction (particularly by the reaction of glycidyl methacrylate with GMA in the presence of acid). The presence of these cross-linkers may

require further purification steps or may be detrimental to any polymer prepared by polymerisation of the obtained monomer. Yet further the process of Refojo requires neutralisation of H_2SO_4 with $\text{Ba}(\text{OH})_2$ and extraction with a toxic flammable solvent.

- 5 The distillation of GMA to prepare purified GMA followed by addition of cross-linker is also practised in the art. Distillation is however both difficult and costly. GMA is high boiling and therefore costs of distillation are high. Distillation typically gives losses of 15-20% of the product to be purified. Moreover, GMA may polymerise during distillation and valuable monomer lost. Yet further, the equipment which may be required to perform
10 the distillation e.g. falling film evaporator, is expensive

Clearly these prior art methods do not provide suitable control of the amount of cross-linker present in the monomer and therefore do not allow for control of the degree of cross-linking during polymerisation. The monomers obtained by the prior art may contain
15 too much cross-linker for some applications or require expensive and difficult purification. Moreover, the prior art methods which attempt to provide pure monomer or to provide monomer comprising cross-linker are very labour intensive and include the use of hazardous chemicals, including toxic chemicals and flammable solvents, and hazardous process steps.

20

Further prior art methods for preparing GMA polymers are disclosed in US 4338419, FR 8207595, WO 93/0841 and Ezrielev et al, Vysokomol. Soedin. Ser. B, 20(10), 777-9, Hild, Makromol. Chem. 177, 1947-1972 (1976) and Beinert et al, Die Makromolekulare Chemie, 175, 2069-2077 (1974)


25

US-A-5532289 discloses a process for forming a soft contact lens. According to the claims of this patent the lens is formed from a copolymer consisting essentially of 2,3-dihydroxypropyl methacrylate (GMA) and 2-hydroxyethyl methacrylate. Hydroxyethyl methacrylate is sometimes referred to as HEMA. The process of US-A-5532289 requires
30 a pre-distillation step wherein GMA is distilled. Hence, the process of US-A-5532289 is laborious and costly.

WO 98/07055 discloses a process of preparing an ocular device (such as a contact lens) consisting essentially of GMA and HEMA, the process comprising the following steps: a) copolymerising a second monomer and a first monomer having attached to it a modifier group, thereby to form a first polymer having associated with it the modifier group; and b) 5 modifying all or some the modifier group associated with the first polymer to form a second polymer different from the first polymer thereby to form the ocular device consisting essentially of GMA and HEMA.

The present invention seeks to overcome the problems associated with the known 10 processes for preparing polymers.

According to a first aspect of the present invention there is provided a process for the preparation of a polymerisable composition comprising a cross-linker and a polymerisable monomer of formula I




15

(I)

comprising the steps of :

(i) contacting a compound of formula II



20

(II)

with an immobilised acid,

wherein X, Y, Z, R¹, P and Q are independently selected from a hydrocarbyl group or hydrogen and wherein A is (CH₂)_n wherein n is 0 or 1;

25

(ii) neutralising the product of step (i) such that the cross-linker is formed.

According to a second aspect of the present invention there is provided an ocular device (such as a contact lens) prepared by the process according to the present invention.

- 5 By the term "cross-linker" we mean a compound which increases the degree of cross-linking of a monomer during polymerisation when compared to the polymerisation of the monomer in the absence of the cross-linker.

The present invention may provide a number of advantages.

10

- The present invention may allow for the amount of cross-linker present in the composition to be controlled. Thus, the present invention provides a composition comprising a polymerisable monomer wherein the degree and/or rate of cross-linking of the polymerisable monomer may be controlled. Moreover, the concentration of cross-linker
15 may be controlled such that further additions of cross-linker are possible to achieve the desired/optimum degree and/or rate of cross-linking during polymerisation.

- The present invention has the advantage that because of the low initial cross-linker concentration in the monomer, controlled additions of further cross-linker to achieve the
20 desired/optimum level are possible. In contrast, if monomer e.g. GMA, in accordance with the prior art is used, the level of cross-linker is often already too high to allow further additions without detriment to the mechanical properties of the final polymer, such as a lens.

- 25 It will be appreciated by a person skilled in the art that at least one of X, Y, Z or R¹ is a polymerisable group such that the compound of formula I is a polymerisable monomer. In a preferred aspect, R¹ is a polymerisable group.

- In a preferred aspect of the process of the present invention the acid is a strong acid. By
30 the term "strong acid" it is meant an acid having a pKa of less than 3.

In a preferred aspect of the process of the present invention the acid is immobilised on an ion exchange resin. Preferably the ion exchange resin is Amberlyst 15, obtainable from Röhm and Haas.

- 5 In a preferred aspect of the process of the present invention, the product of step (i) is neutralised by contacting the product with an immobilised alkali. Preferably the immobilised alkali is an immobilised hydroxide. More preferably the immobilised hydroxide is Amberjet 4400 (OH) obtainable from Röhm and Haas.
- 10 As mentioned above, preferably R^1 is a polymerisable group. Preferably, R^1 is selected from hydrocarbyl group, and hydrocarbyl esters, preferably unsaturated hydrocarbyl esters.

The term "hydrocarbyl group" as used herein means a group comprising at least C and H
15 and may optionally comprise one or more other suitable substituents. Examples of such substituents may include halo-, alkoxy-, nitro-, hydroxy, carboxyl, epoxy, acrylic, hydrocarbon, N-acyl, or cyclic group etc. In addition to the possibility of the substituents being a cyclic group, a combination of substituents may form a cyclic group. If the hydrocarbyl group comprises more than one C then those carbons need not
20 necessarily be linked to each other. For example, at least two of the carbons may be linked *via* a suitable element or group. Thus, the hydrocarbyl group may contain hetero atoms. Suitable hetero atoms will be apparent to those skilled in the art and include, for instance, sulphur, nitrogen and oxygen.

- 25 The term "hydrocarbyl ester" as used herein means a hydrocarbyl group comprising a -C(O)-O- group.

The term "unsaturated hydrocarbyl ester" as used herein means a hydrocarbyl ester comprising at least one carbon-carbon double bond or at least one carbon-carbon triple
30 bond.

Preferably, the hydrocarbyl group is a linear or a branched group. The branched group may contain one or more branches.

In one aspect, the linear or a branched hydrocarbyl group may contain from 1 to 20 carbon atoms, from 1 to 15 carbon atoms, from 1 to 10 carbon atoms, from 1 to 5 carbon atoms, or from 1 to 3 carbon atoms.

The linear or a branched hydrocarbyl group may be saturated or unsaturated. In one aspect, the linear or a branched hydrocarbyl group may be saturated.

10

Preferably, the hydrocarbyl group comprises an alkyl backbone. The backbone may be interrupted by one or more non-alkyl groups. The non-alkyl groups may be selected from ester, ether and combinations thereof.

In one aspect, the alkyl backbone may contain from 1 to 20 carbon atoms, from 1 to 15 carbon atoms, from 1 to 10 carbon atoms, from 1 to 5 carbon atoms, or from 1 to 3 carbon atoms.

The alkyl backbone may contain one or more alkyl groups branched from the alkyl backbone. In one aspect, each alkyl branch may contain from 1 to 20 carbon atoms, from 1 to 15 carbon atoms, from 1 to 10 carbon atoms, from 1 to 5 carbon atoms, or from 1 to 3 carbon atoms.

The hydrocarbyl group may be a cyclic group. In this regard, the hydrocarbyl group can be a single ring group or a polycyclic group. Here, the term "polycyclic" includes fused and non-fused ring structures including combinations thereof.

At least one of the cyclic groups of the polycyclic group may be a heterocyclic group (a heterocycle) or a non-heterocyclic group.

30

The cyclic group or at least one of the cyclic groups of the polycyclic group may be a saturated ring structure or an unsaturated ring structure (such as an aryl group).

The hydrocarbyl group may contain any one or more of C, H, O, Si, N, P, halogen (including Cl, Br and I), S and P. In the preferred aspect wherein the hydrocarbyl group comprises an alkyl backbone, the alkyl backbone may be interrupted by one or more of
 5 any one or more of C, H, O, Si, N, P, halogen (including Cl, Br and I), S and P.


Preferably, the hydrocarbyl group is a hydrocarbon group.

Here the term "hydrocarbon group" means any one of an alkyl group, an alkenyl group,
 10 an alkynyl group, an acyl group, which groups may be linear, branched or cyclic, or an aryl group. The term hydrocarbon also includes those groups but wherein they have been optionally substituted. If the hydrocarbon is a branched structure having substituent(s) thereon, then the substitution may be on either the hydrocarbon backbone or on the branch; alternatively the substitutions may be on the hydrocarbon backbone
 15 and on the branch.

The hydrocarbon group may have from 1 to 20 carbon atoms, from 1 to 15 carbon atoms, from 1 to 10 carbon atoms, from 1 to 5 carbon atoms, or from 1 to 3 carbon atoms.

20

In a preferred embodiment R^1 is a group of formula III



wherein R^2 is selected from methyl, ethyl, propyl and butyl and R^3 is selected from an
 25 unsaturated C_{1-5} alkyl. In a highly preferred embodiment R^2 is CH_3 and R^3 is $=\text{CH}_2$.


Preferably, X, Y, P and Q of formulae given in the present specification are independently selected from a hydrocarbyl group and hydrogen. Preferably, the hydrocarbyl group is a hydrocarbon group. More preferably the hydrocarbyl group is a

hydrocarbon group having from 1 to 20 carbons. Yet more preferably, the hydrocarbyl group is selected from methyl, ethyl, propyl and butyl

In a highly preferred embodiment X is H, Y is H, Z is H, n=0, P is CH₃, Q is CH₃ and R¹ is a group of formula III, in which R² is CH₃ and R³ is =CH₂.


When a compound of formula II is contacted with an immobilised acid to provide a polymerisable monomer of formula I, an acid is formed as a by-product during the reaction. For example, when 2,2-dimethyl-1,3-dioxolan-4-yl methyl methacrylate (GMAK) is contacted with an immobilised acid to provide GMA, methacrylic acid is formed albeit in a low concentration. In a preferred aspect of the present invention, the acid is neutralised in step (ii) such that a cross-linker is formed, wherein the cross-linker is glycerol dimethacrylate (DGMA).

Thus in a highly preferred aspect the present invention provides a process for the preparation of a polymerisable composition comprising a cross-linker and a polymerisable monomer of formula I



comprising the steps of

(i) contacting a compound of formula II




with an immobilised acid,
wherein X is H

II

Y is H

Z is H

A is (CH₂)₀P is CH₃5 Q is CH₃and wherein R¹ is a group of formula IIIin which R² is CH₃ and R³ is =CH₂;

10

(ii) neutralising the product of step (i) by contacting the product with an immobilised hydroxide such that the cross-linker is formed, wherein the cross-linker is glycerol dimethacrylate.

15 In other words, in a highly preferred aspect, the present invention provides a process for the preparation of a composition comprising glyceryl methacrylate (GMA), and glycerol dimethacrylate comprising the steps of (i) contacting (2,2-dimethyl-1,3-dioxolan-4-yl) methyl methacrylate (GMAK) with an immobilised acid; (ii) neutralising the product of step (i) by contacting the product with an immobilised hydroxide such that the glycerol
20 dimethacrylate is formed,

In a preferred embodiment of the present invention the immobilised acid is contacted with the compound of formula II in the presence of water.

25 In a preferred embodiment of the present invention the process further comprises providing means for containing the immobilised acid, contacting the immobilised acid with the compound of formula II and passing a gas through the immobilised acid. In this preferred aspect of the present invention extremely high conversions have been achieved. When GMAK was contacted with immobilised acid a conversion of >99.9%
30 was achieved.

Preferably the gas contains oxygen. More preferably, the gas is air.

Preferably the means for containing the immobilised acid comprises a fluidised bed
5 reactor.

In a further preferred aspect of the present invention the process comprises extracting the gas from the means for containing the immobilised acid after the gas has passed through the immobilised acid. The extracted gas may contain a reaction product of the
10 contact of the compound of formula II with the immobilised acid. The reaction product may be of the formula $P-C(O)-Q$. By removing the reaction product, the equilibrium $II \rightleftharpoons I + P-C(O)-Q$ will be driven towards I. Thus the rate of conversion and/or ultimate conversion of I will be increased and, in a preferred aspect, essentially quantitative conversion may be achieved.

15

It will be appreciated that reaction product $P-C(O)-Q$ is a volatile compound. By the term "volatile compound" we mean that the compound has a boiling point of less than 150°C and/or is capable of forming an azeotrope with water.

20 Thus, in one preferred aspect of the present invention the compound of formula II is or is part of a polymer. However, as explained above, the compound of formula II is preferably a monomer.

In a preferred aspect the process of the present invention further comprises the step of
25 polymerising the polymerisable composition to provide a medical device, in particular an ocular device such as a contact lens.

The present invention is very advantageous for preparing ocular devices, such as contact lenses (both hard and soft contact lenses), intraocular lenses, interocular lenses and
30 intercorneal implants, as well as prostheses and hydrogel articles. In this regard, the present invention not only enables the ocular devices to be made more easily but also it allows, by providing a greater choice of possible degrees and/or rates of cross-linking,

greater control over any one of the shrinkage, the dimensional consistency, the swell, the water sensitivity, the hydrophobicity or the hydrophilicity, or combinations thereof, of the resultant polymer.

- 5 The medical device and/or polymerisable composition may also comprise conventional additional components such as any one or more of emulsifiers, stabilisers, surface active agents, initiators (such as photoinitiators), inhibitors, dispersants, oxidising agents, reducing agents, viscosity modifiers, catalysts, binders, activators, accelerators, tackifiers, plasticizers, saponification agents, chain transfer agents, cross-linking agents,
- 10 surfactants, fillers, dyes, metal salts, and solvents.

By way of example, the surfactants and dispersants can be salts of fatty rosin and naphthenic acids, condensation products of naphthalene sulphonic acid and formaldehyde of low molecular weight, carboxylic polymers and copolymers of the

15 appropriate hydrophile-lipophile balance, higher alkyl sulfates, such as sodium lauryl sulfate, alkyl aryl sulfonates, such as dodecylbenzene sulfonate, sodium or potassium isopropylbenzene sulfonates or isopropyl-naphthalene sulfonates; sulfosuccinates, such as sodium dioctylsulfosuccinate alkali metal higher alkyl sulfosuccinates, *e.g.* sodium octyl sulfosuccinate, sodium N-methyl-N-palmitoyl-taurate, sodium oleyl isethionate,

20 alkali metal salts of alkylaryl polyethoxyethanol sulfates or sulfonates, *e.g.* sodium t-octylphenoxy-polyethoxyethyl sulfate having 1 to 5 oxyethylene units. Typical polymerisation inhibitors that can be used include hydroquinone, monomethyl ether, benzoquinone, phenothiazine and methylene blue.

- 25 In a preferred embodiment the dye is selected from the group consisting of 2-hydroxybenzophenone, oxidiazoles, salicylic acid, resorcinol monobenzoate, benzotriazole, preferably 2H-benzotriazole, benzothiazoloazine, preferably 2N-benzothi-azoloazine, α -cyano- β -phenylcinnamic acid, polyalkylpiperidine and derivatives thereof.

30

Preferably, the dye is selected from benzotriazole, in particular 2H-benzotriazole and derivatives thereof.

The composition and/or medical device of the present invention may comprise one or more additional comonomers. Examples of the one or more additional comonomers that can be used in the present invention include one of: (alkyl and cycloalkyl) acrylates; (alkyl and cycloalkyl) methacrylates; free-radical polymerisable olefinic acids, including alkoxy-, alkylphenoxy-, alkylphenoxy-(polyethyleneoxide)-, vinyl ester-, amine substituted (including quaternary ammonium salts thereof), nitrile-, halo-, hydroxy-, and acid substituted (for example phospho- or sulpo-) derivatives thereof; and other suitable ethylenically unsaturated polymerisable moieties; including combinations thereof.

5 Preferably the alkyl and cycloalkyl groups contain up to 20 carbon atoms, e.g. (C_1 - C_{20} alkyl and C_1 - C_{20} cycloalkyl) acrylates, and (C_1 - C_{20} alkyl and C_1 - C_{20} cycloalkyl) methacrylates. In more detail, typical comonomers include any one of methyl acrylate, ethyl acrylate, n-propyl acrylate, isopropyl acrylate, n-butyl acrylate, isobutyl acrylate, t-butyl acrylate, isobornyl acrylate, pentyl acrylate, hexyl acrylate, octyl acrylate, iso-octyl

15 acrylate, nonyl acrylate, lauryl acrylate, stearyl acrylate, eicosyl acrylate, 2-ethylhexyl acrylate, cyclohexyl acrylate, cycloheptyl acrylate, methyl methacrylate, ethyl methacrylate, hydroxymethylacrylate, hydroxymethylmethacrylate, propyl methacrylate, n-butyl methacrylate, t-butyl methacrylate, isobutyl methacrylate, pentyl methacrylate, hexyl methacrylate, cyclohexyl methacrylate, 2-ethylhexyl methacrylate, isobornyl methacrylate,

20 heptyl methacrylate, cycloheptyl methacrylate, octyl methacrylate, iso-octyl methacrylate, nonyl methacrylate, decyl methacrylate, lauryl methacrylate, eicosyl methacrylate, dodecyl acrylate, pentadecyl acrylate, cetyl acrylate, stearyl acrylate, eicosyl acrylate, isodecyl acrylate, vinyl stearate, nonylphenoxy-(ethyleneoxide)₁₋₂₀ acrylate, octadecene, hexadecene, tetradecene, dodecene, dodecyl methacrylate, pentadecyl methacrylate, cetyl

25 methacrylate, stearyl methacrylate, eicosyl methacrylate, isodecyl methacrylate, nonylphenoxy-(ethyleneoxide)₁₋₂₀ methacrylate, acrylic acid, methacrylic acid, fumaric acid, crotonic acid, itaconic acid, fumaric anhydride, crotonic anhydride, itaconic anhydride, maleic acid, maleic anhydride, styrene, alpha-methyl styrene, vinyl toluene, acrylonitrile, methacrylonitrile, ethylene, vinyl acetate, vinyl chloride, vinylidene chloride,

30 acrylamide, methacrylamide, methacrylamide 2-cyanoethyl acrylate, 2-cyanoethyl methacrylate, dimethylaminoethyl methacrylate, dimethylaminopropyl methacrylate t-butylaminoethyl methacrylate, glycidyl acrylate, glycidyl methacrylate, glyceryl acrylate,

glyceryl methacrylate, benzyl acrylate, benzyl methacrylate, phenyl acrylate, phenyl methacrylate, vinyl pyridine, vinyl pyrrolidine, siloxanes, silanes and mixtures thereof. Other polymerisable monomers are disclosed in US-A-2879178, US-A-3037006, US-A-3502627, US-A-3037969 and US-A-3497485.

5

Preferred comonomers include any one of glyceryl methacrylate (GMA), (2,2 dimethyl-1,3-dioxolan-4-yl) methyl methacrylate (GMAK), hydroxy ethyl methacrylate (HEMA), methacrylic acid, acrylic acid, GYMA, N-vinyl pyrrolidone, alkyl methacrylates (such as C₁₋₂₀ alkyl methacrylates, more preferably C₁₋₁₅ alkyl methacrylates, more preferably C₁₋₁₀ alkyl methacrylates, more preferably C₁₋₅ alkyl methacrylates, such as methyl methacrylate), alkyl acrylates (such as C₁₋₂₀ alkyl acrylates, more preferably C₁₋₁₅ alkyl acrylates, more preferably C₁₋₁₀ alkyl acrylates, more preferably C₁₋₅ alkyl acrylates, such as methyl acrylate), aryl methacrylates, aryl acrylates, diacetone acrylamide, acrylamide, methacrylamide, N-alkyl acrylamides (such as C₁₋₂₀ N-alkyl acrylamides, more preferably C₁₋₁₅ N-alkyl acrylamides, more preferably C₁₋₁₀ N-alkyl acrylamides, more preferably C₁₋₅ N-alkyl acrylamides, such as methyl acrylamide), N-alkyl methacrylamides (such as C₁₋₂₀ N-alkyl methacrylamides, more preferably C₁₋₁₅ N-alkyl methacrylamides, more preferably C₁₋₁₀ N-alkyl methacrylamides, more preferably C₁₋₅ N-alkyl methacrylamides, such as methyl methacrylamide), vinyl acetate, vinyl esters, styrene, other substituted olefins, N-dialkyl acrylamides (such as C₁₋₂₀ N-dialkyl acrylamides, more preferably C₁₋₁₅ N-dialkyl acrylamides, more preferably C₁₋₁₀ N-dialkyl acrylamides, more preferably C₁₋₅ N-dialkyl acrylamides, such as N N dimethyl acrylamide), N-dialkyl methacrylamides (such as C₁₋₂₀ N-dialkyl methacrylamides, more preferably C₁₋₁₅ N-dialkyl methacrylamides, more preferably C₁₋₁₀ N-dialkyl methacrylamides, more preferably C₁₋₅ N-dialkyl methacrylamides, such as N N dimethyl methacrylamide), 3-methacryloxypropyl tris (trimethylsilyl siloxy) silane (TRIS monomer), fluoro substituted alkyl and aryl acrylates and methacrylates (preferably wherein the alkyl is C₁₋₂₀ alkyl, more preferably C₁₋₁₅ alkyl, more preferably C₁₋₁₀ alkyl, more preferably C₁₋₅ alkyl), and combinations thereof.

30 More preferred comonomers include any one of glyceryl methacrylate (GMA), (2,2 dimethyl-1,3-dioxolan-4-yl) methyl methacrylate (GMAK), 2-hydroxy ethyl methacrylate

(2-HEMA), methacrylic acid, acrylic acid and glycidyl methacrylate, or combinations thereof.

The lists of comonomers also include substituted derivatives of those monomers, such as
5 halogenated monomers, especially fluorinated monomer derivatives, and acetal and ketal derivatives.

The polymerisable monomer of the composition of the present invention and the one or more additional comonomers may be selected so that the composition and/or ocular device
10 of the present invention consists essentially of GMA and HEMA.

In a preferred aspect the present invention also provides an ocular device (such as a contact lens) obtained by the process of the present invention wherein the ocular device comprises HEMA in amounts of from 80-20%; GMA in amounts of from 20-80% by
15 weight; and optionally a cross-linking polymerised monomer in an amount of 5% or less; and wherein the ocular device contains less than 0.01% methacrylic acid.

In a preferred aspect of the present invention the compound of formula II is a derivative of GMA such as (2,2-dimethyl-1,3-dioxolan-4-yl) methyl methacrylate (GMAK). GMAK
20 can be prepared following the teachings of Mori *et al* ([1994] *Macromolecules* 27 pp 35-39) and Oguchi *et al* *Polym Eng. Sci.* ([1990] 30 449). This preferred process of the present invention is also of particular interest as GMAK can be readily synthesised from cheap, commercially available materials and it can be prepared in a pure state, i.e. free from the substances normally present in commercial GMA, especially cross-linking
25 substances.

In a preferred aspect the process of the present invention comprises the step of polymerising the polymerisable monomer of formula I. Any typical, suitable polymerisation method may be used. The preferred method is free radical polymerisation,
30 thermal or UV initiated.

A polymer prepared in accordance with the present invention may be fabricated as buttons or cast moulded or spun cast lenses.

The invention will now be described, by way of example only, with reference to the
5 accompanying drawings in which:-

Figure 1 shows a reaction scheme of a preferred process in accordance with the present invention.

Figure 2 shows a graph.

10

EXAMPLES

1. Conversion of GMAK To Glycerine Methacrylate (GMA)

15 The method involves the acid catalysed hydrolysis of the ketal (GMAK) with a strong acid cation exchange resin.

Reagents Employed

20	GMAK (washed)	2880 ml
	Deionised water	921 ml
	Amberlyst 15 (wet) cation exchange resin	288 g

GMAK was obtained was prepared by transesterification of methyl methacrylate and
25 Solketal (2,2-dimethyl-4-hydroxymethyl-1,3-dioxolane).

Before use the Amberlyst 15 (wet) was repeatably washed with deionised water to remove acidic impurities.

30 3000 ml of GMAK is washed with its own volume of deionised water to remove any Solketal. If the GMAK contains a high concentration of Solketal separation will be difficult.

The reagents are placed in a 5 litre bottle and a stream (11 litre/min) of filtered air of ambient temperature (15 to 18°C) passed through the mixture for 48 hours.

- 5 The cation exchange resin is then filtered off using a Buchner funnel and flask.

288 g of well washed Amberjet 4400 (OH) anion exchange resin is added to the filtrate and stirred for one hour to neutralise the methacrylic acid. The resin is then filtered off using a Buchner funnel and flask.

10

The filtrate is transferred to a 2 litre amber glass bottle and a rapid stream of dry filtered air passed through to reduce the water content to < 3%. 50ppm of methyl ether of hydroquinone is added as an inhibitor.

- 15 A yield of 1860 g of GMA was obtained. The cross-linker content was 0.8% glyceryl methacrylate. Details of samples analysed by UV and RI detection are given below. The data are also illustrated in Figure 2.

Composition by UV Detector (%)					Composition by RI Detector (%)			
Sample	GMA	MEHQ	GDMA	GMAK	Glycerol	GMA	GDMA	GMAK
1	99.37	0.04	0.84	0.11	3.02	99.11	0.67	0.00
2	95.12	0.04	2.25	0.05	3.03	95.30	2.01	0.00
3	98.00	0.04	1.59	0.01	2.59	97.95	1.41	0.00
4	97.41	0.04	1.41	0.05	3.40	97.23	1.29	0.00
5	94.13	0.03	1.41	2.26	3.02	94.15	1.24	2.18
6	94.08	0.05	1.35	2.02	3.00	93.84	1.14	1.81
7	100.11	0.05	1.38	0.01	2.60	100.80	1.16	0.00
8	92.98	0.04	1.44	0.01	2.69	93.53	1.34	0.00
9	99.39	0.04	1.57	0.38	1.63	99.39	1.42	0.00
10	91.89	0.03	1.40	0.06	3.14	91.94	1.06	0.00
11	95.11	0.04	1.41	0.39	3.09	94.30	1.23	0.00
12	97.58	0.04	1.29	0.04	3.64	98.04	1.06	0.00
13	97.77	0.04	1.45	0.04	3.23	96.96	1.24	0.00
14	97.73	0.05	1.58	0.59	2.80	98.04	1.40	0.47
Mean	96.48	0.04	1.46	0.43	2.92	96.47	1.26	0.32
St. Dev	2.57	0.00	0.29	0.75	0.47	2.63	0.29	0.72

20 2. Cast Moulding

10g of GMA (prepared in Example 1) was blended with 10g of HEMA. Azo-isobutyronitrile (AIBN) (0.2%) was dissolved in the mixture which was then filtered. The mixture was charged into polypropylene moulds which were assembled and heated

to 120°C for 30 minutes. The cured lenses were ejected and equilibrated in saline solution. The resulting hydrogel lenses had a water content of 60%.

3. Spin Casting

5 10g of GMA (prepared in Example 1) was blended with 10g of HEMA. Benzoin methyl ether (0.2%) was dissolved in the mixture which was then filtered. The mixture was charged into PVC moulds designed for spin casting. After passage through a bank of UV lamps the cured lenses were removed from the moulds by exposure to warm water and then equilibrated in saline.

10


4. Buttons

10g of GMA (prepared in Example 1) was blended with 10g of HEMA. Isopropyl perdicarbonate (0.1%) was dissolved in the mixture which was then filtered. The mixture was charged into polypropylene button moulds which were sealed and immersed in a
15 water bath. After 16 hours at 32° C the clear colourless buttons were ejected and heated to 120°C for 1 hour and allowed to cool to 50°C at a rate of 17°C/hr. Lenses were cut from the buttons and equilibrated in saline.

20 All publications mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described methods and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the
25 invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in chemistry or related fields are intended to be within the scope of the following claims.

CLAIMS


1. A process for the preparation of a polymerisable composition comprising a cross-linker and a polymerisable monomer of formula I



(I)

comprising the steps of :

(i) contacting a compound of formula II



(II)

with an immobilised acid,

wherein X, Y, Z, R¹, P and Q are independently selected from a hydrocarbyl group or hydrogen and wherein A is (CH₂)_n wherein n is 0 or 1;

(ii) neutralising the product of step (i) such that the cross-linker is formed.


2. A process according to claim 1 wherein the acid is a strong acid.

3. A process according to claim 1 or 2 wherein the acid is immobilised on an ion exchange resin.

4. A process according to any one of the preceding claims wherein X and Y are independently selected from hydrocarbon groups having from 1 to 20 carbon atoms and hydrogen.

5. A process according to any one of the preceding claims wherein R¹ is selected from hydrocarbon groups having from 1 to 20 carbon atoms, and hydrocarbyl esters, preferably unsaturated hydrocarbyl esters.

6. A process according any one the preceding claims wherein R¹ is a group of formula III



(III)

wherein R² is selected from methyl, ethyl, propyl and butyl and R³ is selected from an unsaturated C₁₋₅ alkyl.

7. A process according to claim 6 wherein R² is CH₃ and R³ is =CH₂.

8. A process according to any one of the preceding claims wherein X is H, Y is H, Z is H, n=0, R¹ is a group of formula III, in which R² is CH₃ and R³ is =CH₂.

9. A process according to any one of the preceding claims comprising providing means for containing the immobilised acid, contacting the immobilised acid with the compound of formula II and passing a gas through the immobilised acid.

10. A process according to claim 9 wherein the gas is air.

11. A process according to claim 9 or 10 wherein the immobilised acid is contacted with the compound of formula II in the absence of an organic solvent.

12. A process according to any one of the preceding claims step (i) is performed in the presence of water.

13. A process according to any one of claims 9 to 12 wherein the means for containing the immobilised acid comprises a fluidised bed reactor.

14. A process according to any one of claims 9 to 13 wherein the process comprises extracting the gas from the means for containing the immobilised acid after the gas has passed through the immobilised acid.

5

15. A process according to any one of the preceding claims wherein the process further comprises the step of polymerising the polymerisable monomer of formula I.

16. A process according to claim 15 wherein acid formed during the process is not
10 neutralised prior to polymerisation.

17. A process according to claim 16 wherein the acid is selected from methacrylic acid and acrylic acid.

15 18. A process according to claim 15, 16 or 17 further comprising forming an ocular device from the polymer.

19. A polymerisable monomer, polymer or composition obtainable in accordance with process as defined in any one of claims 1 to 18.

20

20. A polymerisable monomer, polymer or composition obtained in accordance with a process as defined in any one of claims 1 to 18.

21. An ocular device prepared in accordance with a process as defined in any one of
25 claims 1 to 18.




Figure 1

2/2




Figure 2

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/GB 00/00780

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07C67/297 C07C69/54 C08F120/20 G02B1/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07C C08F C08L G02B

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BEILSTEIN Data, WPI Data, PAJ, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4 056 496 A (MANCINI WILLIAM L ET AL) 1 November 1977 (1977-11-01) cited in the application the whole document ----	1-21
A	GB 2 097 952 A (TOYO CONTACT LENS) 10 November 1982 (1982-11-10) page 9, line 13 - line 27 ----	1-21
A	G.M. COPPOLA: "Amberlyst-15, a superior acid catalyst for the cleavage of acetals" SYNTHESIS, no. 12, December 1984 (1984-12), pages 1021-1023, XP002140104 Georg Thieme Verlag, Stuttgart, DE ISSN: 0039-7881 the whole document -----	1

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

14 June 2000

Date of mailing of the international search report

30/06/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

English, R

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 00/00780

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4056496 A	01-11-1977	US 4180308 A	25-12-1979
		AR 216881 A	15-02-1980
		AT 339596 B	25-10-1977
		AT 842673 A	15-02-1977
		AU 6070173 A	27-03-1975
		BE 805215 A	25-03-1974
		CA 1002235 A	21-12-1976
		CH 621562 A	13-02-1981
		DD 109880 A	20-11-1974
		DD 113556 A	12-06-1975
		DE 2349528 A	18-04-1974
		DK 44675 A	04-08-1975
		DK 150526 B	16-03-1987
		ES 419240 A	01-03-1976
		FR 2201307 A	26-04-1974
		GB 1419437 A	31-12-1975
		IL 43340 A	30-07-1976
		IT 995537 B	20-11-1975
		JP 1426042 C	25-02-1988
		JP 58009121 A	19-01-1983
		JP 62032456 B	15-07-1987
		JP 1158649 C	25-07-1983
		JP 49116187 A	06-11-1974
		JP 57050803 B	29-10-1982
		NL 7313318 A, B,	04-04-1974
		SE 398647 B	09-01-1978
		SU 609473 A	30-05-1978
		US 4401372 A	30-08-1983
		US 3957362 A	18-05-1976
		ZA 7307138 A	30-04-1975
GB 2097952 A	10-11-1982	JP 57181524 A	09-11-1982
		JP 58065411 A	19-04-1983
		AU 550604 B	27-03-1986
		AU 8268182 A	04-11-1982
		CA 1182614 A	19-02-1985
		DE 3215918 A	02-12-1982
		FR 2505055 A	05-11-1982
		AU 545440 B	11-07-1985
		AU 7916382 A	22-07-1982
		CA 1187645 A	21-05-1985
		DE 3200479 A	26-08-1982
		FR 2497967 A	16-07-1982
		GB 2091750 A, B	04-08-1982
		US 4451629 A	29-05-1984